These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

630 related articles for article (PubMed ID: 33165832)

  • 1. Ubiquitin-proteasome system (UPS) as a target for anticancer treatment.
    Park J; Cho J; Song EJ
    Arch Pharm Res; 2020 Nov; 43(11):1144-1161. PubMed ID: 33165832
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Deubiquitinating enzyme inhibitors and their potential in cancer therapy.
    Crosas B
    Curr Cancer Drug Targets; 2014; 14(6):506-16. PubMed ID: 25088039
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Repurposing old drugs as new inhibitors of the ubiquitin-proteasome pathway for cancer treatment.
    Yang H; Chen X; Li K; Cheaito H; Yang Q; Wu G; Liu J; Dou QP
    Semin Cancer Biol; 2021 Jan; 68():105-122. PubMed ID: 31883910
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Overview of proteasome inhibitor-based anti-cancer therapies: perspective on bortezomib and second generation proteasome inhibitors versus future generation inhibitors of ubiquitin-proteasome system.
    Dou QP; Zonder JA
    Curr Cancer Drug Targets; 2014; 14(6):517-36. PubMed ID: 25092212
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Targeting Deubiquitinating Enzymes and Autophagy in Cancer.
    Mooneyham A; Bazzaro M
    Methods Mol Biol; 2017; 1513():49-59. PubMed ID: 27807830
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Screening for E3-ubiquitin ligase inhibitors: challenges and opportunities.
    Landré V; Rotblat B; Melino S; Bernassola F; Melino G
    Oncotarget; 2014 Sep; 5(18):7988-8013. PubMed ID: 25237759
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The role of the ubiquitin-proteasome pathway in cancer development and treatment.
    Ding F; Xiao H; Wang M; Xie X; Hu F
    Front Biosci (Landmark Ed); 2014 Jun; 19(6):886-95. PubMed ID: 24896323
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Targeting the ubiquitin proteasome system in haematological malignancies.
    Crawford LJ; Irvine AE
    Blood Rev; 2013 Nov; 27(6):297-304. PubMed ID: 24183816
    [TBL] [Abstract][Full Text] [Related]  

  • 9. NEDD4: a promising target for cancer therapy.
    Ye X; Wang L; Shang B; Wang Z; Wei W
    Curr Cancer Drug Targets; 2014; 14(6):549-56. PubMed ID: 25088038
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Discovering proteasomal deubiquitinating enzyme inhibitors for cancer therapy: lessons from rational design, nature and old drug reposition.
    Patel K; Ahmed ZS; Huang X; Yang Q; Ekinci E; Neslund-Dudas CM; Mitra B; Elnady FA; Ahn YH; Yang H; Liu J; Dou QP
    Future Med Chem; 2018 Sep; 10(17):2087-2108. PubMed ID: 30066579
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The ubiquitin-proteasome system and its potential application in hepatocellular carcinoma therapy.
    Chen YJ; Wu H; Shen XZ
    Cancer Lett; 2016 Sep; 379(2):245-52. PubMed ID: 26193663
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The 26S proteasome is a multifaceted target for anti-cancer therapies.
    Grigoreva TA; Tribulovich VG; Garabadzhiu AV; Melino G; Barlev NA
    Oncotarget; 2015 Sep; 6(28):24733-49. PubMed ID: 26295307
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Proteasome-associated deubiquitinases and cancer.
    Mofers A; Pellegrini P; Linder S; D'Arcy P
    Cancer Metastasis Rev; 2017 Dec; 36(4):635-653. PubMed ID: 29134486
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Targeting the ubiquitin+proteasome system in solid tumors.
    Driscoll JJ; Woodle ES
    Semin Hematol; 2012 Jul; 49(3):277-83. PubMed ID: 22726552
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Deubiquitinating enzymes as therapeutic targets in cancer.
    Lim KH; Baek KH
    Curr Pharm Des; 2013; 19(22):4039-52. PubMed ID: 23181570
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Proteasome substrate receptors and their therapeutic potential.
    Osei-Amponsa V; Walters KJ
    Trends Biochem Sci; 2022 Nov; 47(11):950-964. PubMed ID: 35817651
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Therapeutically targeting the SUMOylation, Ubiquitination and Proteasome pathways as a novel anticancer strategy.
    Driscoll JJ; Dechowdhury R
    Target Oncol; 2010 Dec; 5(4):281-9. PubMed ID: 21125340
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Targeting the ubiquitin proteasome system: beyond proteasome inhibition.
    Xolalpa W; Perez-Galan P; Rodríguez MS; Roué G
    Curr Pharm Des; 2013; 19(22):4053-93. PubMed ID: 23181575
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The therapeutic potential of deubiquitinating enzyme inhibitors.
    Colland F
    Biochem Soc Trans; 2010 Feb; 38(Pt 1):137-43. PubMed ID: 20074048
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A patent review of the ubiquitin ligase system: 2015-2018.
    Li X; Elmira E; Rohondia S; Wang J; Liu J; Dou QP
    Expert Opin Ther Pat; 2018 Dec; 28(12):919-937. PubMed ID: 30449221
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 32.